Yousif Capital Management LLC Makes New $214,000 Investment in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

Yousif Capital Management LLC purchased a new position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 2,216 shares of the biotechnology company’s stock, valued at approximately $214,000.

Several other institutional investors have also added to or reduced their stakes in the business. Barclays PLC boosted its holdings in BioMarin Pharmaceutical by 31.6% in the third quarter. Barclays PLC now owns 5,573,157 shares of the biotechnology company’s stock worth $493,111,000 after acquiring an additional 1,336,886 shares in the last quarter. Ameriprise Financial Inc. boosted its holdings in BioMarin Pharmaceutical by 5.6% in the third quarter. Ameriprise Financial Inc. now owns 5,163,949 shares of the biotechnology company’s stock worth $456,906,000 after acquiring an additional 275,436 shares in the last quarter. Fort Washington Investment Advisors Inc. OH boosted its holdings in BioMarin Pharmaceutical by 10.7% in the third quarter. Fort Washington Investment Advisors Inc. OH now owns 1,308,245 shares of the biotechnology company’s stock worth $115,754,000 after acquiring an additional 126,680 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in BioMarin Pharmaceutical by 2.6% in the third quarter. Charles Schwab Investment Management Inc. now owns 1,304,797 shares of the biotechnology company’s stock worth $115,448,000 after acquiring an additional 33,592 shares in the last quarter. Finally, Northern Trust Corp boosted its holdings in BioMarin Pharmaceutical by 3.7% in the third quarter. Northern Trust Corp now owns 1,219,814 shares of the biotechnology company’s stock worth $107,929,000 after acquiring an additional 43,695 shares in the last quarter. Institutional investors and hedge funds own 98.71% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts recently commented on BMRN shares. Canaccord Genuity Group decreased their target price on BioMarin Pharmaceutical from $91.00 to $89.00 and set a “hold” rating for the company in a report on Friday, April 26th. Citigroup decreased their target price on BioMarin Pharmaceutical from $94.00 to $91.00 and set a “neutral” rating for the company in a report on Thursday, April 25th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $110.00 target price on shares of BioMarin Pharmaceutical in a report on Thursday, April 25th. Scotiabank lifted their target price on BioMarin Pharmaceutical from $83.00 to $85.00 and gave the stock a “sector perform” rating in a report on Thursday, April 25th. Finally, Piper Sandler decreased their target price on BioMarin Pharmaceutical from $115.00 to $107.00 and set an “overweight” rating for the company in a report on Friday, February 23rd. Seven analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $107.50.

BioMarin Pharmaceutical Stock Down 0.4 %

BioMarin Pharmaceutical stock opened at $82.10 on Tuesday. The stock has a market capitalization of $15.59 billion, a PE ratio of 76.73, a price-to-earnings-growth ratio of 1.30 and a beta of 0.34. BioMarin Pharmaceutical Inc. has a 12 month low of $76.02 and a 12 month high of $99.56. The business has a 50 day simple moving average of $86.73 and a 200-day simple moving average of $89.02. The company has a debt-to-equity ratio of 0.12, a current ratio of 2.74 and a quick ratio of 1.70.

BioMarin Pharmaceutical (NASDAQ:BMRN) last issued its quarterly earnings results on Thursday, February 22nd. The biotechnology company reported $0.49 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.44 by $0.05. The firm had revenue of $646.21 million for the quarter, compared to analyst estimates of $639.53 million. BioMarin Pharmaceutical had a return on equity of 5.34% and a net margin of 8.31%. The business’s revenue was up 20.2% on a year-over-year basis. During the same period in the previous year, the company posted $0.11 earnings per share. On average, analysts anticipate that BioMarin Pharmaceutical Inc. will post 1.98 EPS for the current fiscal year.

Insider Transactions at BioMarin Pharmaceutical

In other news, CAO Erin Burkhart sold 2,286 shares of BioMarin Pharmaceutical stock in a transaction that occurred on Wednesday, April 10th. The stock was sold at an average price of $90.00, for a total value of $205,740.00. Following the sale, the chief accounting officer now directly owns 16,156 shares of the company’s stock, valued at $1,454,040. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other BioMarin Pharmaceutical news, EVP Jeffrey Robert Ajer sold 4,000 shares of the business’s stock in a transaction on Tuesday, March 5th. The stock was sold at an average price of $87.07, for a total transaction of $348,280.00. Following the transaction, the executive vice president now owns 94,047 shares of the company’s stock, valued at $8,188,672.29. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CAO Erin Burkhart sold 2,286 shares of the business’s stock in a transaction on Wednesday, April 10th. The stock was sold at an average price of $90.00, for a total value of $205,740.00. Following the transaction, the chief accounting officer now directly owns 16,156 shares in the company, valued at approximately $1,454,040. The disclosure for this sale can be found here. Insiders have sold 105,079 shares of company stock valued at $9,220,236 over the last ninety days. Insiders own 1.85% of the company’s stock.

BioMarin Pharmaceutical Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.